{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:00:53Z","timestamp":1787695253723,"version":"build-2784847793"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00044-026-03567-w","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:27:20Z","timestamp":1778855240000},"page":"1031-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Piperazine derivatives as anticancer agents: a medicinal chemistry review of structure, mechanism, and clinical translation"],"prefix":"10.1007","volume":"35","author":[{"given":"Trapti","family":"Porwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Salahuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"3567_CR1","doi-asserted-by":"publisher","first-page":"108703","DOI":"10.1016\/j.bioorg.2025.108703","volume":"163","author":"H Singh","year":"2025","unstructured":"Singh H, Kumar R, Mazumder A, et al. Novel pyrazoline-piperazine conjugates as anticancer and antibacterial agents: integrating synthesis, in vitro, QSAR, molecular docking, and MD simulation studies. Bioorg Chem. 2025;163:108703. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108703.","journal-title":"Bioorg Chem"},{"issue":"8","key":"3567_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353. https:\/\/doi.org\/10.1002\/ijc.31937.","journal-title":"Int J Cancer"},{"key":"3567_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31679-8","author":"MH Forouzanfar","year":"2016","unstructured":"Forouzanfar MH, Afshin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational risks. Lancet. 2016. https:\/\/doi.org\/10.1016\/S0140-6736(16)31679-8.","journal-title":"Lancet"},{"issue":"3","key":"3567_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3322\/caac.21556","volume":"69","author":"KR Yabroff","year":"2019","unstructured":"Yabroff KR, Gansler T, Wender RC, et al. Minimizing the burden of cancer in the United States. CA Cancer J Clin. 2019;69(3):166\u201383. https:\/\/doi.org\/10.3322\/caac.21556.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3567_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jnci\/djae068","volume":"116","author":"CJ Bradley","year":"2024","unstructured":"Bradley CJ, Yabroff KR, Shih YC, et al. Clinic-based interventions for improving access to care. J Natl Cancer Inst. 2024;116(6):786.","journal-title":"J Natl Cancer Inst"},{"key":"3567_CR6","doi-asserted-by":"publisher","first-page":"1127704","DOI":"10.3389\/fimmu.2023.1127704","volume":"14","author":"M Strzelec","year":"2023","unstructured":"Strzelec M, Detka J, Mieszczak P, et al. Immunomodulation\u2014a general review. Front Immunol. 2023;14:1127704. https:\/\/doi.org\/10.3389\/fimmu.2023.1127704.","journal-title":"Front Immunol"},{"key":"3567_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2022.03.007","volume":"155","author":"V Yazbeck","year":"2022","unstructured":"Yazbeck V, Alesi E, Myers J, et al. An overview of chemotoxicity and radiation toxicity in cancer therapy. Adv Cancer Res. 2022;155:1\u201327 https:\/\/doi.org\/10.1016\/bs.acr.2022.03.007","journal-title":"Adv Cancer Res"},{"issue":"4","key":"3567_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"MT Manzari","year":"2021","unstructured":"Manzari MT, Shamay Y, Kiguchi H, et al. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351\u201370. https:\/\/doi.org\/10.1038\/s41578-020-00269-6.","journal-title":"Nat Rev Mater"},{"issue":"4","key":"3567_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","volume":"13","author":"N El-Sayes","year":"2021","unstructured":"El-Sayes N, Vito A, Mossman K, et al. Tumor heterogeneity. Cancers. 2021;13(4):806.","journal-title":"Cancers"},{"issue":"19","key":"3567_CR10","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.2174\/1871520622666220404082648","volume":"22","author":"N Kumar","year":"2022","unstructured":"Kumar N, Goel N, et al. Heterocyclic compounds in anticancer drug discovery. Anticancer Agents Med Chem. 2022;22(19):3196\u2013207. https:\/\/doi.org\/10.2174\/1871520622666220404082648.","journal-title":"Anticancer Agents Med Chem"},{"issue":"8","key":"3567_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/molecules25081909","volume":"25","author":"N Kerru","year":"2020","unstructured":"Kerru N, Gummidi L, Maddila S, et al. Nitrogen-containing molecules and biological applications. Molecules. 2020;25(8):1909. https:\/\/doi.org\/10.3390\/molecules25081909.","journal-title":"Molecules"},{"issue":"7","key":"3567_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/13543776.2016.1189902","volume":"26","author":"AK Rathi","year":"2016","unstructured":"Rathi AK, Syed R, Shin HS, et al. Piperazine derivatives for therapeutic use. Expert Opin Ther Pat. 2016;26(7):777\u201397. https:\/\/doi.org\/10.1080\/13543776.2016.1189902.","journal-title":"Expert Opin Ther Pat"},{"key":"3567_CR13","doi-asserted-by":"publisher","unstructured":"Rigneault H, et al. Synthesis of functionalized heterocycles. Focus Microscopy. 2022;255. https:\/\/doi.org\/10.34894\/VQ1DJA.","DOI":"10.34894\/VQ1DJA"},{"key":"3567_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/0115734064304396240415110015","volume":"20","author":"M Faizan","year":"2024","unstructured":"Faizan M, Kumar R, Mazumder A, Salahuddin, Kukreti N, Kumar A, et al. Synthetic protocols, structural activity relationship, and biological activity of piperazine and its derivatives. Med Chem. 2024;20:753\u2013780.","journal-title":"Med Chem"},{"issue":"6","key":"3567_CR15","doi-asserted-by":"publisher","first-page":"e14537","DOI":"10.1111\/cbdd.14537","volume":"103","author":"M Faizan","year":"2024","unstructured":"Faizan M, et al. Medicinal chemistry of piperazines. Chem Biol Drug Des. 2024;103(6):e14537. https:\/\/doi.org\/10.1111\/cbdd.14537.","journal-title":"Chem Biol Drug Des"},{"key":"3567_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11112-X","author":"S Sharma","year":"2025","unstructured":"Sharma S, Babu MA, Kumar R, et al. Pyrimidine-based pharmacophore in anticancer drugs. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11112-X.","journal-title":"Mol Divers"},{"key":"3567_CR17","doi-asserted-by":"publisher","first-page":"108595","DOI":"10.1016\/j.bioorg.2025.108595","volume":"162","author":"S Tripathi","year":"2025","unstructured":"Tripathi S, Kumar R, Debnath A, et al. Piperazine\u2013oxadiazole\u2013quinoline conjugates. Bioorg Chem. 2025;162:108595. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108595.","journal-title":"Bioorg Chem"},{"key":"3567_CR18","doi-asserted-by":"publisher","first-page":"13121","DOI":"10.3390\/ijms252313121","volume":"25","author":"K Wu","year":"2024","unstructured":"Wu K, Kwon SH, Zhou X, et al. Bioavailability in small molecule drugs. Int J Mol Sci. 2024;25:13121.","journal-title":"Int J Mol Sci"},{"key":"3567_CR19","doi-asserted-by":"publisher","unstructured":"Singh S, Kumar R, Tripathi S, et al. Piperazines as anticancer agents. Chem Biol Drug Des. 2025;105(3). https:\/\/doi.org\/10.1111\/cbdd.70077.","DOI":"10.1111\/cbdd.70077"},{"issue":"7","key":"3567_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00775-010-0676-4","volume":"15","author":"P Gramatica","year":"2010","unstructured":"Gramatica P, Papa E, Luini M, et al. Antiproliferative Pt(IV) complexes. J Biol Inorg Chem. 2010;15(7):1157\u201369. https:\/\/doi.org\/10.1007\/s00775-010-0676-4.","journal-title":"J Biol Inorg Chem"},{"issue":"1","key":"3567_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.2006.09.7030","volume":"25","author":"RF Ozols","year":"2007","unstructured":"Ozols RF, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening. J Clin Oncol. 2007;25(1):146\u201362. https:\/\/doi.org\/10.1200\/JCO.2006.09.7030.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3567_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/17460441.2024.2322990","volume":"19","author":"PSM Pinheiro","year":"2024","unstructured":"Pinheiro PSM, Franco LS, Montagnoli TL, et al. Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opin Drug Discov. 2024;19(4):451\u201370. https:\/\/doi.org\/10.1080\/17460441.2024.2322990.","journal-title":"Expert Opin Drug Discov"},{"key":"3567_CR23","doi-asserted-by":"publisher","unstructured":"Ramos P, Bentires-Alj M et al. (2015) Mechanism-based cancer therapy: resistance to therapy and therapy for resistance. Oncogene. https:\/\/doi.org\/10.1038\/onc.2014.314","DOI":"10.1038\/onc.2014.314"},{"key":"3567_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13065-025-01133-6","volume":"19","author":"M Alhilal","year":"2025","unstructured":"Alhilal M, Alhilal S, Gomha SM, Farag B, Sabancilar I, et al. Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chem. 2025;19:255. https:\/\/doi.org\/10.1186\/s13065-025-01133-6.","journal-title":"BMC Chem"},{"issue":"26","key":"3567_CR25","doi-asserted-by":"publisher","first-page":"1907625","DOI":"10.1002\/adfm.201907625","volume":"30","author":"Z Hassan","year":"2020","unstructured":"Hassan Z, Matt Y, Begum S, et al. Assembly of molecular building blocks into complex systems. Adv Funct Mater. 2020;30(26):1907625. https:\/\/doi.org\/10.1002\/adfm.201907625.","journal-title":"Adv Funct Mater"},{"issue":"9","key":"3567_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17460441.2023.2234285","volume":"18","author":"D Grenier","year":"2023","unstructured":"Grenier D, Audebert S, Preto J, et al. Linkers in fragment-based drug design. Expert Opin Drug Discov. 2023;18(9):987\u20131009. https:\/\/doi.org\/10.1080\/17460441.2023.2234285.","journal-title":"Expert Opin Drug Discov"},{"issue":"5","key":"3567_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ipha.2024.03.001","volume":"2","author":"M Shah","year":"2024","unstructured":"Shah M, Patel M, Prajapati M, et al. Computational transformation in drug discovery: docking and QSAR. Intell Pharm. 2024;2(5):589\u201395. https:\/\/doi.org\/10.1016\/j.ipha.2024.03.001.","journal-title":"Intell Pharm"},{"key":"3567_CR28","doi-asserted-by":"publisher","unstructured":"Nemr MTM, Mohamed LW, Sayed HS, et al. Pyrazolopyrimidine derivatives as multitarget anticancer agents. Drug Dev Res. 2026;87(2). https:\/\/doi.org\/10.1002\/ddr.70259.","DOI":"10.1002\/ddr.70259"},{"key":"3567_CR29","doi-asserted-by":"crossref","unstructured":"Sharma V, Das R, Sharma D, et al. Green chemistry approach towards piperazine anticancer agents. J Mol Struct; 2023.","DOI":"10.1016\/j.molstruc.2023.136089"},{"key":"3567_CR30","doi-asserted-by":"publisher","unstructured":"Ali MI, Santali EY, El-Haggar R, et al. Quinoxaline\u2013isoxazole\u2013piperazine conjugates targeting EGFR. Chem Biol Drug Des. 2024;103(3). https:\/\/doi.org\/10.1111\/cbdd.14499.","DOI":"10.1111\/cbdd.14499"},{"key":"3567_CR31","doi-asserted-by":"publisher","first-page":"112640","DOI":"10.1016\/j.ejmech.2020.112640","volume":"204","author":"P Bhatia","year":"2020","unstructured":"Bhatia P, et al. Quinazoline-based EGFR inhibitors: SAR and docking studies. Eur J Med Chem. 2020;204:112640. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112640.","journal-title":"Eur J Med Chem"},{"key":"3567_CR32","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1021\/acs.jmedchem.1c00240","volume":"64","author":"AN Fallica","year":"2021","unstructured":"Fallica AN, Pittal\u00e0 V, Modica MN, Salerno L, Romeo G, et al. Recent advances in the development of sigma receptor ligands as cytotoxic agents: a medicinal chemistry perspective. J Med Chem. 2021;64:7926\u201362. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00240.","journal-title":"J Med Chem"},{"issue":"1","key":"3567_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/molecules29010068","volume":"29","author":"MN Romanelli","year":"2023","unstructured":"Romanelli MN, Braconi L, Gabellini A, et al. Synthetic approaches to piperazine-containing FDA-approved drugs (2011\u20132023). Molecules. 2023;29(1):68.","journal-title":"Molecules"},{"issue":"10","key":"3567_CR34","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/ph17101320","volume":"17","author":"G Mohamed Andreozzi","year":"2024","unstructured":"Mohamed Andreozzi G, Corvino A, Severino B, et al. Arylpiperazine derivatives and cancer: a new challenge in medicinal chemistry. Pharmaceuticals. 2024;17(10):1320.","journal-title":"Pharmaceuticals"},{"key":"3567_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35237-2","author":"ZY Zheng","year":"2018","unstructured":"Zheng ZY, Li J, Li F, et al. Induction of N-Ras degradation by flunarizine-mediated autophagy. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-35237-2.","journal-title":"Sci Rep"},{"key":"3567_CR36","unstructured":"Ewieda SY, Ahmed EM, Halim PA, et al. Pyridazinone derivatives as EGFR inhibitors. Bioorg Chem; 2026."},{"key":"3567_CR37","unstructured":"Ewieda SY, Ahmed EM, Gohar NA, et al. Pyridazinone scaffolds as dual EGFR\/VEGFR-2 inhibitors. Bioorg Chem; 2025."},{"issue":"6","key":"3567_CR38","doi-asserted-by":"publisher","first-page":"736","DOI":"10.55730\/1300-0527.3767","volume":"49","author":"Co\u015fkunA \u00dcnverY","year":"2025","unstructured":"\u00dcnverYCo\u015fkunA, \u00c7elik F, et al. New bis-piperazine derivatives: synthesis, characterization (IR, NMR), gamma-ray absorption, antimicrobial activity, molecular docking and dynamics study. Turk J Chem. 2025;49(6):736\u201353. . https:\/\/doi.org\/10.55730\/1300-0527.3767","journal-title":"Turk J Chem"},{"key":"3567_CR39","unstructured":"Sharma A, Wakode S, Fayaz F, et al. Piperazine scaffold as a promising therapeutic nucleus. Curr Pharm Des; 2020."},{"key":"3567_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E, et al. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:84. https:\/\/doi.org\/10.1186\/s13045-018-0624-2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3567_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"35","key":"3567_CR42","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.2174\/0929867326666190808122929","volume":"27","author":"MJ Akhtar","year":"2019","unstructured":"Akhtar MJ, Yar MS, Sharma VK, et al. Benzimidazole hybrids for anticancer potential. Curr Med Chem. 2019;27(35):5970\u20136014. https:\/\/doi.org\/10.2174\/0929867326666190808122929.","journal-title":"Curr Med Chem"},{"issue":"7","key":"3567_CR43","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1021\/cr900026u","volume":"109","author":"A Skladanowski","year":"2009","unstructured":"Skladanowski A, Bozko P, Sabisz M, et al. DNA structure checkpoints and drug targeting. Chem Rev. 2009;109(7):2951\u201373. https:\/\/doi.org\/10.1021\/cr900026u.","journal-title":"Chem Rev"},{"key":"3567_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-94-007-2869-1_7","volume":"942","author":"J Estaquier","year":"2012","unstructured":"Estaquier J, Vallette F, Vayssiere JL, et al. Mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157\u201383. https:\/\/doi.org\/10.1007\/978-94-007-2869-1_7.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"3567_CR45","doi-asserted-by":"publisher","first-page":"e0191523","DOI":"10.1371\/journal.pone.0191523","volume":"13","author":"A Jaudan","year":"2018","unstructured":"Jaudan A, Sharma S, Abd Malek SN, et al. Induction of apoptosis by pinostrobin in human cervical cancer cells. PLoS ONE. 2018;13(2):e0191523. https:\/\/doi.org\/10.1371\/journal.pone.0191523.","journal-title":"PLoS ONE"},{"key":"3567_CR46","unstructured":"Aboelez MO, Ali MAEAA, Kamel MS, et al. Diaminothienothiophene derivatives as EGFR and tubulin inhibitors. Bioorg Chem; 2025."},{"issue":"20","key":"3567_CR47","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.3390\/cancers13205226","volume":"13","author":"MC Laisne","year":"2021","unstructured":"Laisne MC, Michallet S, Lafanech\u00e8re L. Characterization of microtubule destabilizing drugs: a quantitative cell-based assay that bridges the gap between tubulin-based and cytotoxicity assays. Cancers. 2021;13(20):5226. https:\/\/doi.org\/10.3390\/cancers13205226.","journal-title":"Cancers"},{"issue":"1","key":"3567_CR48","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1080\/14756366.2021.1931861","volume":"36","author":"RH Zhang","year":"2021","unstructured":"Zhang RH, Guo HY, Deng H, et al. Piperazine skeleton in structural modification of natural products. J Enzyme Inhib Med Chem. 2021;36(1):1165\u201397. https:\/\/doi.org\/10.1080\/14756366.2021.1931861.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"3567_CR49","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/genes11060642","volume":"11","author":"T Wilhelm","year":"2020","unstructured":"Wilhelm T, Said M, Naim V, et al. DNA replication stress and chromosomal instability. Genes. 2020;11(6):642.","journal-title":"Genes"},{"key":"3567_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-14723-4","author":"D Shahriarynejad","year":"2025","unstructured":"Shahriarynejad D, Dastyafteh N, Naz F, et al. Piperazine-based benzimidazole derivatives as urease inhibitors. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-14723-4.","journal-title":"Sci Rep"},{"key":"3567_CR51","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1007\/s00018-021-03926-3","volume":"78","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Fujita M, et al. DNA damage responses and replication stress. Cell Mol Life Sci. 2021;78:6763\u201373. https:\/\/doi.org\/10.1007\/s00018-021-03926-3.","journal-title":"Cell Mol Life Sci"},{"issue":"25","key":"3567_CR52","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.1073\/pnas.1120476109","volume":"109","author":"SS Foster","year":"2012","unstructured":"Foster SS, De S, Johnson LK, et al. Cell cycle and DNA repair pathway effects in tumor suppression. Proc Natl Acad Sci USA. 2012;109(25):9953\u20138. https:\/\/doi.org\/10.1073\/pnas.1120476109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3567_CR53","unstructured":"Ewieda SY, Salem M, Elshewy A, et al. Thiazolopyrimidine derivatives targeting topoisomerase II. Bioorg Chem; 2025."},{"key":"3567_CR54","doi-asserted-by":"publisher","first-page":"108839","DOI":"10.1016\/j.bioorg.2025.108839","volume":"164","author":"RA Hassan","year":"2025","unstructured":"Hassan RA, Sonousi A, Abdou AM, et al. Thieno [2,3-d] pyrimidine derivatives as topoisomerase II inhibitors: design, synthesis, anticancer evaluation, and in silico studies. Bioorg Chem. 2025;164:108839. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108839","journal-title":"Bioorg Chem"},{"key":"3567_CR55","doi-asserted-by":"publisher","unstructured":"Verma A, Saraf SK et al. (2008) Piperazine derivatives: a review. Eur J Med Chem 43(5):897\u2013905. https:\/\/doi.org\/10.1016\/j.ejmech.2007.07.017 abmoust Oncogenesis 12(1):16.","DOI":"10.1016\/j.ejmech.2007.07.017"},{"issue":"1","key":"3567_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41389-023-00459-8","volume":"12","author":"D Vanauberg","year":"2023","unstructured":"Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023;12(1):16. https:\/\/doi.org\/10.1038\/s41389-023-00459-8.","journal-title":"Oncogenesis"},{"key":"3567_CR57","unstructured":"Zaytseva YY, Rychahou PG, Le AT, et al. Fatty acid synthase inhibitors in colorectal cancer. Oncotarget; 2018."},{"issue":"15","key":"3567_CR58","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.4155\/fmc-2017-0072","volume":"9","author":"MMM El-Miligy","year":"2017","unstructured":"El-Miligy MMM, Abd El Razik HA, Abu-Serie MM, et al. Piperazine-based thiazolidinones as VEGFR2 inhibitors. Future Med Chem. 2017;9(15):1709\u201329. https:\/\/doi.org\/10.4155\/fmc-2017-0072.","journal-title":"Future Med Chem"},{"issue":"12","key":"3567_CR59","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.3390\/pharmaceutics14122600","volume":"14","author":"D Ruzic","year":"2022","unstructured":"Ruzic D, Ellinger B, Djokovic N, et al. Piperazine-based HDAC inhibitors with anti-breast cancer activity. Pharmaceutics. 2022;14(12):2600.","journal-title":"Pharmaceutics"},{"key":"3567_CR60","unstructured":"Klameth L et al. (2017) Expression of carbonic anhydrase IX in cancer models. Dissertation, Med Univ Vienna."},{"key":"3567_CR61","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1039\/D5MD00348B","volume":"16","author":"XQ Zhou","year":"2025","unstructured":"Zhou XQ, Huang YX, Liang QL, et al. A novel 1,8-naphthalimide-piperazine-amidobenzenesulfonamide derivative targets carbonic anhydrase IX to induce ferroptosis, apoptosis and autophagy in colorectal cancer cells. RSC Med Chem. 2025;16:4427\u201339. https:\/\/doi.org\/10.1039\/D5MD00348B.","journal-title":"RSC Med Chem"},{"issue":"49","key":"3567_CR62","doi-asserted-by":"publisher","first-page":"15882","DOI":"10.1021\/ja065860f","volume":"128","author":"JC Hermann","year":"2006","unstructured":"Hermann JC, Ghanem E, Li Y, et al. Predicting substrates by docking high-energy intermediates. J Am Chem Soc. 2006;128(49):15882\u201391. https:\/\/doi.org\/10.1021\/ja065860f.","journal-title":"J Am Chem Soc"},{"key":"3567_CR63","doi-asserted-by":"publisher","unstructured":"Abdalla M, Elmasry AE, Nemr MTM, et al. Repurposing anti-inflammatory drugs as CDK inhibitors. ChemistrySelect. 2025;10(15). https:\/\/doi.org\/10.1002\/slct.202500175.","DOI":"10.1002\/slct.202500175"},{"key":"3567_CR64","unstructured":"Abd El-Mawgoud HA, AboulMagd AM, Nemr MTM, et al. Thienopyrimidine analogues as VEGFR-2\/AKT inhibitors. Bioorg Chem; 2024."},{"issue":"2","key":"3567_CR65","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.mcpro.2025.100906","volume":"24","author":"W vanBergen","year":"2025","unstructured":"vanBergenW, Nederstigt AE, Heck AJR, et al. Site-specific competitive kinase inhibitor target profiling using phosphonate affinity tags. Mol Cell Proteom. 2025;24(2):100906. https:\/\/doi.org\/10.1016\/j.mcpro.2025.100906","journal-title":"Mol Cell Proteom"},{"key":"3567_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11406-0","author":"L Ma","year":"2025","unstructured":"Ma L, et al. Alepterolic acid derivatives with piperazine moiety as anticancer agents. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11406-0.","journal-title":"Mol Divers"},{"issue":"9","key":"3567_CR67","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/cancers11091245","volume":"11","author":"RK Mongre","year":"2019","unstructured":"Mongre RK, et al. Carbazole-piperazine hybrid targeting BCL-2 in lung cancer. Cancers. 2019;11(9):1245. https:\/\/doi.org\/10.3390\/cancers11091245.","journal-title":"Cancers"},{"key":"3567_CR68","doi-asserted-by":"publisher","first-page":"682366","DOI":"10.3389\/fmed.2021.682366","volume":"8","author":"L Liu","year":"2021","unstructured":"Liu L, Wang M, Li X, et al. Novel agents for cervical cancer treatment by inducing apoptosis. Front Med (Lausanne). 2021;8:682366. https:\/\/doi.org\/10.3389\/fmed.2021.682366.","journal-title":"Front Med (Lausanne)"},{"key":"3567_CR69","doi-asserted-by":"publisher","first-page":"108931","DOI":"10.1016\/j.bioorg.2025.108931","volume":"165","author":"X Wang","year":"2025","unstructured":"Wang X, Ma L, Sun Y, et al. Structural hybridization of alepterolic acid with piperazine-benzamide motifs yields potent anticancer agents. Bioorg Chem. 2025;165:108931. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108931","journal-title":"Bioorg Chem"},{"issue":"45","key":"3567_CR70","doi-asserted-by":"publisher","first-page":"28313","DOI":"10.1039\/c6ra24662a","volume":"7","author":"V Abbot","year":"2017","unstructured":"Abbot V, Sharma P, Dhiman S, et al. Small hybrid heteroaromatics in cancer research. RSC Adv. 2017;7(45):28313\u201349. https:\/\/doi.org\/10.1039\/c6ra24662a.","journal-title":"RSC Adv"},{"issue":"14","key":"3567_CR71","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.2174\/0929867330666230622142505","volume":"31","author":"Y Cui","year":"2023","unstructured":"Cui Y, Zhang J, Zhang G, et al. Strategies to overcome multidrug resistance in tubulin inhibitors. Curr Med Chem. 2023;31(14):1874\u201395. https:\/\/doi.org\/10.2174\/0929867330666230622142505.","journal-title":"Curr Med Chem"},{"issue":"11","key":"3567_CR72","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3390\/pharmaceutics15112581","volume":"15","author":"M Beljkas","year":"2023","unstructured":"Beljkas M, Ilic A, Cebzan A, et al. Targeting HDAC6 in dual-target cancer therapy. Pharmaceutics. 2023;15(11):2581.","journal-title":"Pharmaceutics"},{"key":"3567_CR73","doi-asserted-by":"publisher","first-page":"108694","DOI":"10.1016\/j.bioorg.2025.108694","volume":"163","author":"FA Mamdouh","year":"2025","unstructured":"Mamdouh FA, Mohamed FA, Salem IM, Fouad A, et al. Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase\u2013carbonic anhydrase inhibitors with potential anti-tubulin activity. Bioorg Chem. 2025;163:108694. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108694.","journal-title":"Bioorg Chem"},{"key":"3567_CR74","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.bioorg.2025.108728","volume":"163","author":"OA Moustafa","year":"2025","unstructured":"Moustafa OA, Aboelez MAEA, Ali MER, Kamel MS, et al. Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity. Bioorg Chem. 2025;163:108728. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108728.","journal-title":"Bioorg Chem"},{"key":"3567_CR75","doi-asserted-by":"crossref","unstructured":"Winters S, Martin C, Murphy D, et al. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci; 2017.","DOI":"10.1016\/bs.pmbts.2017.07.002"},{"key":"3567_CR76","unstructured":"Zhang ZJ, Liao YT, Wang W, et al. Acetophenone\/piperazinone hybrids as anti-TNBC agents. Bioorg Med Chem Lett; 2024."},{"issue":"18","key":"3567_CR77","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.3390\/molecules29184471","volume":"29","author":"FC da Silva","year":"2024","unstructured":"da Silva FC, Martinho ACC, Ferreira HSV, et al. Phenylsulfonylpiperazine compound in breast cancer cells. Molecules. 2024;29(18):4471.","journal-title":"Molecules"},{"issue":"6","key":"3567_CR78","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/molecules25061426","volume":"25","author":"S Habtemariam","year":"2020","unstructured":"Habtemariam S, et al. Berberine-inspired anticancer approaches. Molecules. 2020;25(6):1426.","journal-title":"Molecules"},{"key":"3567_CR79","doi-asserted-by":"publisher","unstructured":"Zala AR, Kumari P, et al. Benzimidazole, piperazine and piperidine hybrids. ChemistrySelect. 2023;8(37). https:\/\/doi.org\/10.1002\/slct.202301304.","DOI":"10.1002\/slct.202301304"},{"key":"3567_CR80","doi-asserted-by":"publisher","unstructured":"Shi XY, Jiao H, Zhang JK, et al. Arylamide derivatives with piperazine moiety as tubulin inhibitors. J Enzyme Inhib Med Chem. 2023;38(1). https:\/\/doi.org\/10.1080\/14756366.2023.2237701.","DOI":"10.1080\/14756366.2023.2237701"},{"issue":"4","key":"3567_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3109\/14756366.2014.959513","volume":"30","author":"EE Gurdal","year":"2015","unstructured":"Gurdal EE, Durmaz I, Cetin-Atalay R, et al. Benzothiazole-piperazine derivatives cytotoxic activity. J Enzyme Inhib Med Chem. 2015;30(4):649\u201354. https:\/\/doi.org\/10.3109\/14756366.2014.959513.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"3567_CR82","doi-asserted-by":"publisher","DOI":"10.17344\/acsi.2019.5196","author":"A Kucukdumlu","year":"2020","unstructured":"Kucukdumlu A, Tuncbilek M, Guven EB, et al. 6,9-Disubstituted purine analogues cytotoxic activity. Acta Chim Slov. 2020. https:\/\/doi.org\/10.17344\/acsi.2019.5196.","journal-title":"Acta Chim Slov"},{"issue":"22","key":"3567_CR83","doi-asserted-by":"publisher","first-page":"12401","DOI":"10.3390\/ijms252212401","volume":"25","author":"KD Szczepa\u0144skiJ","year":"2024","unstructured":"Szczepa\u0144skiJKD, Korga-Plewko A, et al. Rhodanine-piperazine hybrids as potential VEGFR, EGFR, and HER2 targeting anti-breast cancer agents. Int J Mol Sci. 2024;25(22):12401. https:\/\/doi.org\/10.3390\/ijms252212401","journal-title":"Int J Mol Sci"},{"key":"3567_CR84","unstructured":"Rao BV, Kumar PP, Ramalingam V, et al. Piperazine tethered bergenin hybrids as anticancer agents. RSC Med Chem; 2022."},{"key":"3567_CR85","unstructured":"Kasula M, Myadaraveni P, Palabindela R, et al. EGFR-targeting anticancer agents: docking and DFT studies. SSRN Preprint; 2025."},{"key":"3567_CR86","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra06350g","author":"AB Dhongade","year":"2025","unstructured":"Dhongade AB, Shah U, Patil BN, et al. Quinolinyl-thiazole piperazine hybrids as anti-breast cancer agents. RSC Adv. 2025. https:\/\/doi.org\/10.1039\/d5ra06350g.","journal-title":"RSC Adv"},{"issue":"10","key":"3567_CR87","first-page":"5424","volume":"12","author":"BK Sagar","year":"2021","unstructured":"Sagar BK, Kumar MD, Mahesh B, et al. Piperazine amide derivatives as anticancer agents. Int J Pharm Sci Res. 2021;12(10):5424\u201330.","journal-title":"Int J Pharm Sci Res"},{"issue":"23","key":"3567_CR88","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.3390\/ijms242317041","volume":"24","author":"JM Calder\u00f3n-Monta\u00f1o","year":"2023","unstructured":"Calder\u00f3n-Monta\u00f1o JM, Vega-P\u00e9rez JM, L\u00f3pez-L\u00e1zaro M, et al. 4-Acyl-piperazine derivatives as anticancer agents. Int J Mol Sci. 2023;24(23):17041.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3567_CR89","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/molecules23112788","volume":"23","author":"MR Aouad","year":"2018","unstructured":"Aouad MR, Soliman MA, Alharbi MO, et al. Benzothiazole-piperazine-triazole hybrids as anticancer agents. Molecules. 2018;23(11):2788.","journal-title":"Molecules"},{"key":"3567_CR90","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ejmech.2018.01.044","volume":"146","author":"A Kamal","year":"2018","unstructured":"Kamal A, Bharathi EV, Reddy JS, et al. Benzothiazole derivatives as anticancer agents. Eur J Med Chem. 2018;146:397\u2013412. https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.044.","journal-title":"Eur J Med Chem"},{"key":"3567_CR91","unstructured":"Zhou X, Huang Y, Liang Q, et al. Naphthalimide\u2013piperazine derivatives targeting carbonic anhydrase IX. RSC Med Chem; 2025."},{"key":"3567_CR92","unstructured":"Ning L, Chen D, Han J, et al. Global research trends in ferroptosis in hepatocellular carcinoma. Front Oncol; 2024."},{"issue":"23","key":"3567_CR93","doi-asserted-by":"publisher","first-page":"13135","DOI":"10.3390\/ijms222313135","volume":"22","author":"VA Arzumanian","year":"2021","unstructured":"Arzumanian VA, Kiseleva OI, Poverennaya EV, et al. The HepG2 cell line: 40 years of expertise. Int J Mol Sci. 2021;22(23):13135.","journal-title":"Int J Mol Sci"},{"key":"3567_CR94","doi-asserted-by":"publisher","first-page":"116136","DOI":"10.1016\/j.bmc.2021.116136","volume":"39","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Wang L, Lou J, et al. Design and synthesis of purine derivatives as anticancer agents. Bioorg Med Chem. 2021;39:116136. https:\/\/doi.org\/10.1016\/j.bmc.2021.116136.","journal-title":"Bioorg Med Chem"},{"key":"3567_CR95","unstructured":"Singh D, Patel R, Aggarwal A, et al. Phenylthiazolidinone\u2013piperazine conjugates as anticancer agents. Results Chem; 2024."},{"issue":"46","key":"3567_CR96","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.1002\/slct.201902955","volume":"4","author":"M Reddy Gangireddy","year":"2019","unstructured":"Reddy Gangireddy M, Mantipally M, Gundla R, et al. Piperazine-linked imidazopyridine derivatives as anticancer agents. ChemistrySelect. 2019;4(46):13622\u20139. https:\/\/doi.org\/10.1002\/slct.201902955.","journal-title":"ChemistrySelect"},{"key":"3567_CR97","doi-asserted-by":"publisher","first-page":"113489","DOI":"10.1016\/j.ejmech.2021.113489","volume":"221","author":"NE \u0130bi\u015fK","year":"2021","unstructured":"\u0130bi\u015fKNE, \u00c7al\u0131\u015fkan B, et al. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells. Eur J Med Chem. 2021;221:113489. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113489","journal-title":"Eur J Med Chem"},{"key":"3567_CR98","unstructured":"Guven EB, Sahin ID, Altiparmak D, et al. Purine nucleobase analogs with piperazine as anticancer agents. RSC Med Chem; 2023."},{"issue":"1","key":"3567_CR99","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1080\/14756366.2018.1504041","volume":"33","author":"B \u00c7al\u0131\u015fkan","year":"2018","unstructured":"\u00c7al\u0131\u015fkan B, Sinoplu E, \u0130bi\u015f K, et al. Isoxazole derivatives incorporating arylpiperazine moiety. J Enzyme Inhib Med Chem. 2018;33(1):1352\u201361. https:\/\/doi.org\/10.1080\/14756366.2018.1504041.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"3567_CR100","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s43094-024-00663-9","volume":"10","author":"M Singh","year":"2024","unstructured":"Singh M, Jadhav HR, Choudhary A, et al. Methyl piperazine derivatives as anticancer agents. Future J Pharm Sci. 2024;10(1):88. https:\/\/doi.org\/10.1186\/s43094-024-00663-9.","journal-title":"Future J Pharm Sci"},{"key":"3567_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/srep24172","author":"N Samie","year":"2016","unstructured":"Samie N, Muniandy S, Kanthimathi MS, et al. Piperazine core compound induces death in liver cancer cells. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep24172.","journal-title":"Sci Rep"},{"issue":"1","key":"3567_CR102","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1080\/14756366.2019.1655407","volume":"34","author":"H Chen","year":"2019","unstructured":"Chen H, Qiao C, Miao TT, et al. Piperazine-based MEK inhibitors. J Enzyme Inhib Med Chem. 2019;34(1):1544\u201361. https:\/\/doi.org\/10.1080\/14756366.2019.1655407.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"3567_CR103","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040. Gut. 2023;72(2):338.","journal-title":"Gut"},{"key":"3567_CR104","doi-asserted-by":"publisher","unstructured":"Lingaswamy V, Nukala SK, Srinivas B, et al. Indole\u2013piperazine\u2013triazole conjugates as anticancer agents. ChemistrySelect. 2025;10(17). https:\/\/doi.org\/10.1002\/slct.202405930.","DOI":"10.1002\/slct.202405930"},{"issue":"1","key":"3567_CR105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11094-022-02597-z","volume":"56","author":"M Al-Ghorbani","year":"2022","unstructured":"Al-Ghorbani M, Gouda MA, Baashen M, et al. Piperazine heterocycles as anticancer agents. Pharm Chem J. 2022;56(1):29\u201337. https:\/\/doi.org\/10.1007\/s11094-022-02597-z.","journal-title":"Pharm Chem J"},{"issue":"10","key":"3567_CR106","first-page":"5424","volume":"12","author":"BK Sagar","year":"2021","unstructured":"Sagar BK, Kumar MD, Mahesh B, et al. Piperazine amide derivatives as anticancer agents. Int J Pharm Sci Res. 2021;12(10):5424\u201330.","journal-title":"Int J Pharm Sci Res"},{"key":"3567_CR107","unstructured":"Chopra A, Anderson A, Goyal C, et al. Piperazine-based compounds inhibit microtubule dynamics. J Biol Chem; 2014."},{"key":"3567_CR108","doi-asserted-by":"publisher","first-page":"105551","DOI":"10.1016\/j.bioorg.2021.105551","volume":"119","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang S, Li Y, et al. Piperazine derivatives as potential anticancer agents: recent advances. Bioorg Chem. 2022;119:105551. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105551.","journal-title":"Bioorg Chem"},{"issue":"2","key":"3567_CR109","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11094-020-02172-4","volume":"54","author":"E Manouchehrizadeh","year":"2020","unstructured":"Manouchehrizadeh E, Mostoufi A, Tahanpesar E, et al. Piperidine and piperazine derivatives of dichloroacetate. Pharm Chem J. 2020;54(2):148\u201353. https:\/\/doi.org\/10.1007\/s11094-020-02172-4.","journal-title":"Pharm Chem J"},{"issue":"8","key":"3567_CR110","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0069-0","volume":"19","author":"CT Supuran","year":"2020","unstructured":"Supuran CT, et al. Carbonic anhydrase inhibitors in cancer therapy. Nat Rev Drug Discov. 2020;19(8):589\u2013607. https:\/\/doi.org\/10.1038\/s41573-020-0069-0.","journal-title":"Nat Rev Drug Discov"},{"key":"3567_CR111","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejmech.2018.10.021","volume":"161","author":"S Kumar","year":"2019","unstructured":"Kumar S, Narasimhan B, et al. Arylpiperazine derivatives as anticancer agents: a review. Eur J Med Chem. 2019;161:298\u2013338. https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.021.","journal-title":"Eur J Med Chem"},{"key":"3567_CR112","unstructured":"Singh S, Paul S, Martins FG, et al. Quinoxaline carbonyl piperazine derivatives as FASN inhibitors. Bioorg Chem; 2025."},{"key":"3567_CR113","doi-asserted-by":"publisher","unstructured":"Mermer A, T\u00fcz\u00fcn B, Da\u015ftan SD, et al. Piperazine-incorporated Schiff base derivatives: biological evaluation and docking studies. J Biochem Mol Toxicol. 2023;37(11). https:\/\/doi.org\/10.1002\/jbt.23465.","DOI":"10.1002\/jbt.23465"},{"issue":"2","key":"3567_CR114","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10495-018-1439-x","volume":"23","author":"R Khanam","year":"2018","unstructured":"Khanam R, Kumar R, Hejazi II, et al. Piperazine\u2013azetidinone derivatives induce apoptosis in HeLa cells. Apoptosis. 2018;23(2):113\u201331. https:\/\/doi.org\/10.1007\/s10495-018-1439-x.","journal-title":"Apoptosis"},{"issue":"5","key":"3567_CR115","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1568026622666220124101234","volume":"22","author":"K Rani","year":"2022","unstructured":"Rani K, Kaur R, Kumar K, et al. Piperazine-based scaffolds in medicinal chemistry. Curr Top Med Chem. 2022;22(5):412\u201330. https:\/\/doi.org\/10.2174\/1568026622666220124101234.","journal-title":"Curr Top Med Chem"},{"key":"3567_CR116","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ejmech.2013.04.017","volume":"64","author":"SL Cao","year":"2013","unstructured":"Cao SL, Han Y, Yuan CZ, et al. Piperazine carbodithioate derivatives of quinazoline as anticancer agents. Eur J Med Chem. 2013;64:401\u20139.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"3567_CR117","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3184\/174751915X14381686689721","volume":"39","author":"B Mistry","year":"2015","unstructured":"Mistry B, Keum YS, Kim DH, et al. Berberine derivatives with piperazine moieties. J Chem Res. 2015;39(8):470\u20134. https:\/\/doi.org\/10.3184\/174751915X14381686689721.","journal-title":"J Chem Res"},{"key":"3567_CR118","unstructured":"Shirzad M, Salahvarzi A, Razzaq S, et al. AI-based nanocarriers in prostate cancer therapy. Crit Rev Oncol Hematol; 2025."},{"key":"3567_CR119","unstructured":"Aminu KS, Uzairu A, Mishra VK, et al. Quinoline-based hybrids as anti-diabetic agents: in silico design. Sci Afr; 2025."},{"key":"3567_CR120","doi-asserted-by":"publisher","unstructured":"Badithapuram V, Nukala SK, Dasari G, et al. Phthalazine\u2013piperazine\u2013pyrazole conjugates as anticancer agents. ChemistrySelect. 2023;8(10). https:\/\/doi.org\/10.1002\/slct.202204329.","DOI":"10.1002\/slct.202204329"},{"key":"3567_CR121","doi-asserted-by":"publisher","DOI":"10.1039\/d4ra05014b","author":"N Wagih","year":"2025","unstructured":"Wagih N, Abdel-Rahman IM, El-Koussi NA, et al. Benzimidazole derivatives targeting epigenetic cancer pathways. RSC Adv. 2025. https:\/\/doi.org\/10.1039\/d4ra05014b.","journal-title":"RSC Adv"},{"key":"3567_CR122","unstructured":"Hacholli VB, Shubha MR, Prabhanajan BH, et al. Coumarin derivatives as anticancer agents. Molecules; 2025."},{"key":"3567_CR123","doi-asserted-by":"publisher","unstructured":"Al-Soud YA et al. (2021) 4-Nitroimidazole derivatives: synthesis and anticancer activity. Arkivoc 2021(8):296\u2013309. https:\/\/doi.org\/10.24820\/ark.5550190.p011.479","DOI":"10.24820\/ark.5550190.p011.479"},{"key":"3567_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1542317","author":"J Chen","year":"2025","unstructured":"Chen J, Pang W, Deng M, et al. Global burden of leukemia: 1990\u20132021 analysis. Front Med. 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1542317.","journal-title":"Front Med"},{"key":"3567_CR125","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2026.2620359","author":"AA Bhat","year":"2026","unstructured":"Bhat AA, Singh I, et al. Pyridine derivatives in anticancer drug discovery. Future Med Chem. 2026. https:\/\/doi.org\/10.1080\/17568919.2026.2620359.","journal-title":"Future Med Chem"},{"key":"3567_CR126","doi-asserted-by":"publisher","unstructured":"Yilmaz AM, et al. Piperazine-linked quinolinequinones targeting cancer proliferation. Chem Biol Drug Des. 2025;105(6). https:\/\/doi.org\/10.1111\/cbdd.70139.","DOI":"10.1111\/cbdd.70139"},{"issue":"1","key":"3567_CR127","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14756366.2020.1861606","volume":"36","author":"MF Ahmed","year":"2020","unstructured":"Ahmed MF, Santali EY, El-Haggar R, et al. Piperazine\u2013chalcone hybrids targeting VEGFR-2 kinase. J Enzyme Inhib Med Chem. 2020;36(1):307\u201318. https:\/\/doi.org\/10.1080\/14756366.2020.1861606.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"3567_CR128","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00044-024-03322-z","volume":"34","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lei M, Zhao Z, et al. Cinnamyl piperazine derivatives: pharmacological review. Med Chem Res. 2025;34(1):19\u201344. https:\/\/doi.org\/10.1007\/s00044-024-03322-z.","journal-title":"Med Chem Res"},{"issue":"6","key":"3567_CR129","first-page":"622","volume":"5","author":"EX She","year":"2013","unstructured":"She EX, Hao Z. A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathways. Am J Transl Res. 2013;5(6):622\u201333.","journal-title":"Am J Transl Res"},{"key":"3567_CR130","doi-asserted-by":"publisher","first-page":"42867","DOI":"10.1021\/acsomega.3c05567","volume":"8","author":"MD Alt\u0131ntop","year":"2023","unstructured":"Alt\u0131ntop MD, Canturk Z, Ozdemir A, et al. Design, synthesis, and evaluation of a new series of 2-pyrazolines as potential antileukemic agents. ACS Omega. 2023;8:42867\u201377. https:\/\/doi.org\/10.1021\/acsomega.3c05567.","journal-title":"ACS Omega"},{"key":"3567_CR131","doi-asserted-by":"publisher","first-page":"117518","DOI":"10.1016\/j.bmc.2023.117518","volume":"96","author":"M Napi\u00f3rkowska","year":"2023","unstructured":"Napi\u00f3rkowska M, Kurpios-Piec D, Kiernozek-Kali\u0144ska E, Le\u015bniak A, Klawikowska M, et al. New aryl-\/heteroarylpiperazine derivatives of 1,7-dimethyl-8,9-diphenyl-4-azatricyclo[5.2.1.0\u00b2,\u2076]dec-8-ene-3,5,10-trione: synthesis and preliminary studies of biological activities. Bioorg Med Chem. 2023;96:117518. https:\/\/doi.org\/10.1016\/j.bmc.2023.117518.","journal-title":"Bioorg Med Chem"},{"key":"3567_CR132","doi-asserted-by":"publisher","unstructured":"Meng J, Qiu C, Lu C, et al. Daidzein-piperazine salt with improved bioavailability. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1385637.","DOI":"10.3389\/fphar.2024.1385637"},{"key":"3567_CR133","doi-asserted-by":"publisher","first-page":"115034","DOI":"10.1016\/j.ejmech.2022.115034","volume":"247","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li X, Chen L, et al. Design and synthesis of chalcone-based hybrids as VEGFR-2 inhibitors. Eur J Med Chem. 2023;247:115034. https:\/\/doi.org\/10.1016\/j.ejmech.2022.115034.","journal-title":"Eur J Med Chem"},{"issue":"34","key":"3567_CR134","doi-asserted-by":"publisher","first-page":"21968","DOI":"10.1039\/D2RA03761K","volume":"12","author":"J Desantis","year":"2022","unstructured":"Desantis J, et al. PROTACs bearing piperazine-containing linkers. RSC Adv. 2022;12(34):21968\u201377. https:\/\/doi.org\/10.1039\/D2RA03761K.","journal-title":"RSC Adv"},{"issue":"6","key":"3567_CR135","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jhet.4588","volume":"60","author":"C Sahu","year":"2023","unstructured":"Sahu C, Chaurasiya A, Chawla PA, et al. Nitrogen-containing heterocycles as topoisomerase II inhibitors. J Heterocycl Chem. 2023;60(6):899\u2013928. https:\/\/doi.org\/10.1002\/jhet.4588.","journal-title":"J Heterocycl Chem"},{"issue":"1","key":"3567_CR136","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","volume":"8","author":"Z Mao","year":"2022","unstructured":"Mao Z, et al. Targeting KRAS(G12D) via salt bridge formation. Cell Discov. 2022;8(1):5. https:\/\/doi.org\/10.1038\/s41421-021-00368-w.","journal-title":"Cell Discov"},{"key":"3567_CR137","doi-asserted-by":"publisher","unstructured":"Irgit A, Kam\u0131s R, Sever B, et al. Structure and dynamics of ABL1 kinase. Arch Pharm. 2025;358(5). https:\/\/doi.org\/10.1002\/ardp.70005.","DOI":"10.1002\/ardp.70005"},{"key":"3567_CR138","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/DDDT.S80207","volume":"9","author":"R Chen","year":"2015","unstructured":"Chen R, Chen B, et al. Role of dasatinib in chronic myeloid leukemia. Drug Des Devel Ther. 2015;9:773\u20139. https:\/\/doi.org\/10.2147\/DDDT.S80207.","journal-title":"Drug Des Devel Ther"},{"key":"3567_CR139","doi-asserted-by":"publisher","first-page":"1154654","DOI":"10.3389\/fphar.2023.1154654","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Li X, Luo P, et al. Abemaciclib derivatives targeting CDK4\/6. Front Pharmacol. 2023;14:1154654. https:\/\/doi.org\/10.3389\/fphar.2023.1154654.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3567_CR140","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1021\/acsmedchemlett.9b00438","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Pasunooti KK, Peng H, et al. Itraconazole analogs as angiogenesis inhibitors. ACS Med Chem Lett. 2020;11(6):1111\u20137. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00438.","journal-title":"ACS Med Chem Lett"},{"key":"3567_CR141","unstructured":"Priya MGR, Solomon VR, Hemavathy N, et al. Quinoline derivatives with piperazine moiety as anti-breast cancer agents. Results Chem; 2024."},{"key":"3567_CR142","doi-asserted-by":"publisher","DOI":"10.1039\/d4ra05091f","author":"DM Mohamed","year":"2024","unstructured":"Mohamed DM, Kheder NA, Sharaky M, et al. Piperazine-based bis(thiazole\/thiadiazole) hybrids as anticancer agents. RSC Adv. 2024. https:\/\/doi.org\/10.1039\/d4ra05091f.","journal-title":"RSC Adv"},{"key":"3567_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02491-6","author":"BS Fegade","year":"2025","unstructured":"Fegade BS, et al. 3-Methoxy flavone derivatives as anti-breast cancer agents. Med Chem Res. 2025. https:\/\/doi.org\/10.1007\/s12672-025-02491-6.","journal-title":"Med Chem Res"},{"key":"3567_CR144","unstructured":"Narmada G, Marupati S, Srinivas B, et al. Quinazoline hybrids as EGFR-targeting agents. J Mol Struct; 2025."},{"key":"3567_CR145","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra03819g","author":"HEN Khasawneh","year":"2025","unstructured":"Khasawneh HEN, Hassan HM, Alharbi AA, et al. 1,2,3-Triazole hybrids as EGFR inhibitors. RSC Adv. 2025. https:\/\/doi.org\/10.1039\/d5ra03819g.","journal-title":"RSC Adv"},{"issue":"1","key":"3567_CR146","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14756366.2020.1861606","volume":"36","author":"MF Ahmed","year":"2021","unstructured":"Ahmed MF, Santali EY, El-Haggar R, et al. Piperazine\u2013chalcone hybrids targeting VEGFR-2 kinase. J Enzyme Inhib Med Chem. 2021;36(1):307\u201318. https:\/\/doi.org\/10.1080\/14756366.2020.1861606.","journal-title":"J Enzyme Inhib Med Chem"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03567-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:48:10Z","timestamp":1782380890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03567-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":146,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03567-w","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}